This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Phase 3 ASX biotech that is close to unlocking its market opportunity. It is expecting to complete its Phase 3 trials during FY26 (the…

ByNick Sundich

19

Feb 2025

Healthcare Stocks Life Sciences Small Caps Stocks

Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!

Recce Pharmaceuticals (ASX:RCE) has completed its Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections) for RECCE® 327 Topical Gel (R327G) and released the results earlier this week.…

ByNick Sundich

10

Feb 2025

Education Life Sciences

Here’s how Australia’s Research and Development Tax Incentive Works

Australia's Research and Development Tax Incentive (R&D Tax Incentive) regime can be useful for pre-commercialisation companies serving as a non-dilutive source of funding. Progressing new medical treatments or technologies to market…

ByNick Sundich

06

Nov 2024

Healthcare Stocks Life Sciences Mid Cap Stocks Small Caps Stocks

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

There are encouraging signs from Recce Pharmaceuticals' (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections). The trial, is nearing completion, but the results to date…

ByNick Sundich

16

Sep 2024

Education Healthcare Stocks

Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs

For ASX biotechs wishing to commercialise drugs in Australia, the Therapeutic Goods Administration (TGA) Special Access Scheme is the next best thing to regulatory approval. Therapeutic goods need to be included…

ByNick Sundich

23

Aug 2024

Healthcare Stocks

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

The list of major milestones of ASX biotech companies is headed with clinical trial results, regulatory approval and commercialisation. However, clinical trials can take a long time, and there are…

ByNick Sundich

22

Aug 2024

Healthcare Stocks

Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason

Recce Pharmaceuticals investors are amongst the few investors in ASX stocks that have a reason to smile right now. Their company has significantly outperformed the broader ASX, sitting in positive…

ByNick Sundich

30

Jul 2024

Healthcare Stocks Small Caps Stocks

These ASX biotechs are working with the US Department of Defence to bring new drugs to market and have a bright future ahead

Think of ASX stocks working with the US Department of Defence, and investors might imagine defence stocks or perhaps even critical mineral project developers. This is not completely untrue. The list…

ByNick Sundich

14

Jun 2024

Healthcare Stocks

How to minimise the risks of biotech shares on the ASX? Here are 4 traits investors should look for

To minimise the risks of biotech shares is a major challenge for investors, but not one that is insurmountable. The biotech sector on the ASX represents a substantial opportunity for…

ByNick Sundich

20

May 2024

Healthcare Stocks Small Caps Stocks

Recce Pharmaceuticals (ASX:RCE): Taking the fight against superbugs to the next level

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Sydney-based company fighting the battle against superbugs, with a legitimate chance of succeeding if the data to date is any guide. Bacterial infections have…

ByNick Sundich

This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!

Here’s how Australia’s Research and Development Tax Incentive Works

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason

These ASX biotechs are working with the US Department of Defence to bring new drugs to market and have a bright future ahead

How to minimise the risks of biotech shares on the ASX? Here are 4 traits investors should look for

Recce Pharmaceuticals (ASX:RCE): Taking the fight against superbugs to the next level

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here